Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models

Lung Cancer

Volumn 42, Issue 3, 2003, Pages 263-274

  Cook, Judith W ^a   Sterman, Daniel H ^a   Singhal, Sunil ^a   Smythe, W Roy ^a   Kaiser, Larry R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Extracellular growth factors; Malignant mesothelioma; Suramin

Indexed keywords

SURAMIN;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; XENOGRAFT;

EID: 0344551797     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00363-5     Document Type: Article

References (25)

1. Antman K.H. Natural history and epidemiology of malignant mesothelioma. Chest. 103:1993;373S-376S.
2. Rusch V.W. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 103:1993;382S-384S.
3. Garlepp M.J., Leong C.C. Biological and immunological aspects of malignant mesothelioma. Eur. Respir. J. 8:1995;643-650.
4. Fitzpatrick D.R., Peroni D.J., Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am. J. Respir. Cell Mol. Biol. 12:1995;455-460.
5. Stein C.A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 53:1993;2239-2248.
6. Yoneda T., Williams P., Rhine C., Boyce B.F., Dunstan C., Mundy G.R. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Res. 55:1995;1989-1993.
7. Takano S., Gately S., Neville M.E.et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 54:1994;2654-2660.
8. Westermann A.M., Dubbelman R., Moolenaar W.H., Beijnen J., Rodenhuis S. Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann. Oncol. 8:1997;801-802.
9. Westermann A.M., Dubbelman R., Baars J.P., Moolenaar W.H., Beijnen J.H., Rodenhuis S. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother. Pharmacol. 46:2000;57-62.
10. Smythe W.R., Hwang H.C., Elshami A.A. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222:1995;78-86.
11. Craighead J.E., Akley N.J., Gould L.B., Libbus B.L. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am. J. Pathol. 129:1987;448-462.
12. Hwang H.C., Smythe W.R., Elshami A.A.et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. 13:1995;7-16.
13. Taylor C.W., Lui R., Fanta P., Salmon S.E. Effects of suramin on in vitro growth of fresh human tumors. J. Natl. Cancer Inst. 84:1992;489-494.
14. Morocz I.A., Lauber B., Schmitter D., Stahel R.A. In vitro effect of suramin on lung tumour cells. Eur. J. Cancer. 29A:1993;245-247.
15. Chahinian A.P., Mandeli J.P., Gluck H., Naim H., Teirstein A.S., Holland J.F. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J. Surg. Oncol. 67:1998;104-111.
16. Motzer R.J., Dmitrovsky E., Miller W.H. Jr.et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer. 72:1993;3313-3317.
17. Motzer R.J., Nanus D.M., O'Moore P.et al. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res. 52:1992;5775-5779.
18. Reed E., Cooper M.R., LaRocca R.V., Bostick-Bruton F., Myers C.E. Suramin in advanced platinum-resistant ovarian cancer. Eur. J. Cancer. 28A:1992;864-866.
19. Myers C., Cooper M., Stein C.et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 110:1992;881-889.
20. Dawson N.A., Cooper M.R., Figg W.D.et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 76:1995;453-462.
21. La Rocca R.V., Meer J., Gilliatt R.W.et al. Suramin-induced polyneuropathy. Neurology. 40:1990;954-960.
22. Scher H.I. Suramin: here to stay!? J. Natl. Cancer Inst. 85:1993;594-597.
23. Scher H.I., Jodrell D.I., Iversen J.M.et al. Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52:1992;64-70.
24. Eisenberger M.A., Reyno L.M., Jodrell D.I.et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J. Natl. Cancer Inst. 85:1993;611-621.
25. Graham S.D. Jr., Napalkov P., Oladele A.et al. Intravesical suramin in the prevention of transitional cell carcinoma. Urology. 45:1995;59-63.